Osteopore signed an agreement with Zimmer Biomet, which will serve as Osteopore’s exclusive distributor for craniofacial products in EMEA and APAC. The multi-year agreement comprises 24 countries in the initial stages of distribution, with an initial focus on EMEA.
Currently, Osteopore markets and sells its craniofacial products in 10 countries across EMEA, Australia, and New Zealand. In 2023, the combined revenue from these countries accounted for 8% to 9% of the company’s annual total revenue. The agreement’s initial emphasis on EMEA enables Osteopore to instantly double its presence in the region.
Key terms of the Agreement:
An initial term of 5 years from the effective date
Minimum purchase commitments and a minimum initial stocking order during the first 12 months from the effective date of the Agreement
Osteopore retains control and ownership of its Intellectual Property including any modifications, improvements, and adaptations
The Agreement comprises customary termination provisions, including those relating to non-performance or breach
Osteopore CEO Dr. Yujing Lim said, “This distribution partnership with Zimmer Biomet is a key milestone in our efforts to step up the commercialization of our craniofacial products. We are pleased Zimmer Biomet sees the value in our craniofacial products and technology, especially with the clinical focus shifting towards regenerative medicine and healing. This Agreement enables Osteopore to leverage Zimmer Biomet’s sales and marketing capabilities, expertise, and network, to boost the reach of our craniofacial products in EMEA and APAC.”
Osteopore signed an agreement with Zimmer Biomet, which will serve as Osteopore’s exclusive distributor for craniofacial products in EMEA and APAC. The multi-year agreement comprises 24 countries in the initial stages of distribution, with an initial focus on EMEA.
Currently, Osteopore markets and sells its craniofacial products in 10...
Osteopore signed an agreement with Zimmer Biomet, which will serve as Osteopore’s exclusive distributor for craniofacial products in EMEA and APAC. The multi-year agreement comprises 24 countries in the initial stages of distribution, with an initial focus on EMEA.
Currently, Osteopore markets and sells its craniofacial products in 10 countries across EMEA, Australia, and New Zealand. In 2023, the combined revenue from these countries accounted for 8% to 9% of the company’s annual total revenue. The agreement’s initial emphasis on EMEA enables Osteopore to instantly double its presence in the region.
Key terms of the Agreement:
An initial term of 5 years from the effective date
Minimum purchase commitments and a minimum initial stocking order during the first 12 months from the effective date of the Agreement
Osteopore retains control and ownership of its Intellectual Property including any modifications, improvements, and adaptations
The Agreement comprises customary termination provisions, including those relating to non-performance or breach
Osteopore CEO Dr. Yujing Lim said, “This distribution partnership with Zimmer Biomet is a key milestone in our efforts to step up the commercialization of our craniofacial products. We are pleased Zimmer Biomet sees the value in our craniofacial products and technology, especially with the clinical focus shifting towards regenerative medicine and healing. This Agreement enables Osteopore to leverage Zimmer Biomet’s sales and marketing capabilities, expertise, and network, to boost the reach of our craniofacial products in EMEA and APAC.”
Copy to clipboard 
